Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATC161
- Development stage
- Unknown
- Lead developer
- Autotac Bio
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
ATC161 is an orally bioavailable small molecule Autophagy-Targeting Chimera (AUTOTAC) developed by Autotac Bio for the treatment of Parkinson's disease and other neurodegenerative disorders. It functions by selectively binding to pathological alpha-synuclein aggregates and the autophagy receptor p62 (SQSTM1), thereby facilitating the degradation of these toxic aggregates via the autophagy-lysosomal pathway. Unlike traditional inhibitors, ATC161 promotes the clearance of existing protein aggregates without affecting the physiological monomeric form of alpha-synuclein. Preclinical data indicate that ATC161 reduces neuroinflammation and improves motor performance in animal models. The compound has received Investigational New Drug (IND) approval for Phase 1 clinical trials in South Korea.
- Other names
- AB-16AB16AB 16
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))SQSTM1 (Sequestosome-1)
Beyond the preview
Go deeper on ATC161.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATC161.